Myriad Genetics, Inc. (MYGN) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low9.0·High40.3
P/FCF
N/A
—
5yr avg: 3588.00
30Y Low10.1·High119.3
P/B Ratio
↓
1.15
↓-35% vs avg
5yr avg: 1.78
30Y Low0.8·High19.3
ROE
↓
-68.5%
↑-159% vs avg
5yr avg: -26.4%
30Y Low-68%·High31%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High2.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MYGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Myriad Genetics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $425M | $574M | $1.2B | $1.6B | $1.2B | $2.2B | $1.5B | $843M | $2.1B | $2.7B | $1.8B |
| Enterprise Value | $485M | $634M | $1.3B | $1.6B | $1.3B | $2.0B | $1.7B | $983M | $2.3B | $2.6B | $1.8B |
| P/E Ratio → | -1.15 | — | — | — | — | — | — | — | 459.17 | 20.53 | 80.75 |
| P/S Ratio | 0.51 | 0.70 | 1.48 | 2.10 | 1.72 | 3.12 | 2.65 | 1.32 | 2.48 | 3.48 | 2.30 |
| P/B Ratio | 1.15 | 1.56 | 1.77 | 2.02 | 1.32 | 2.22 | 1.68 | 0.77 | 1.94 | 2.79 | 2.29 |
| P/FCF | — | — | — | — | — | 3588.00 | — | 16.68 | 28.11 | 25.03 | 17.76 |
| P/OCF | 235.85 | 318.77 | — | — | — | 115.74 | — | 13.88 | 25.22 | 23.22 | 16.74 |
P/E links to full P/E history page with 30-year chart
MYGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.77 | 1.53 | 2.13 | 1.85 | 2.88 | 2.96 | 1.54 | 2.65 | 3.35 | 2.30 |
| EV / EBITDA | — | — | — | — | — | — | — | — | 27.94 | 14.96 | 18.16 |
| EV / EBIT | — | — | — | — | — | — | — | — | 187.63 | — | — |
| EV / FCF | — | — | — | — | — | 3311.17 | — | 19.46 | 29.98 | 24.08 | 17.73 |
MYGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Myriad Genetics, Inc. earns an operating margin of -8.2%. Operating margins have expanded from -34.2% to -8.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -68.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | 69.9% | 68.6% | 70.2% | 71.4% | 68.0% | 70.9% | 76.4% | 77.1% | 77.8% |
| Operating Margin | -8.2% | -8.2% | -14.7% | -34.2% | -20.7% | -27.6% | -35.0% | -36.3% | 0.9% | 15.4% | 6.4% |
| Net Profit Margin | -44.4% | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | -40.2% | -31.2% | 0.5% | 17.0% | 2.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.5% | -68.5% | -17.2% | -31.6% | -12.1% | -2.9% | -22.7% | -18.3% | 0.4% | 15.0% | 2.9% |
| ROA | -42.2% | -42.2% | -11.7% | -22.5% | -8.9% | -2.0% | -15.0% | -12.8% | 0.3% | 10.9% | 2.1% |
| ROIC | -8.7% | -8.7% | -12.0% | -21.7% | -11.9% | -15.4% | -12.8% | -14.1% | 0.5% | 10.9% | 5.1% |
| ROCE | -9.4% | -9.4% | -13.3% | -25.1% | -12.9% | -15.9% | -14.3% | -16.0% | 0.6% | 11.4% | 5.4% |
MYGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $60M ($210M total debt minus $150M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.57 | 0.57 | 0.20 | 0.19 | 0.16 | 0.10 | 0.33 | 0.21 | 0.21 | 0.01 | 0.13 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 2.90 | 0.05 | 1.01 |
| Net Debt / Equity | — | 0.16 | 0.05 | 0.03 | 0.10 | -0.17 | 0.20 | 0.13 | 0.13 | -0.11 | -0.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 1.74 | -0.59 | -0.03 |
| Debt / FCF | — | — | — | — | — | -276.83 | — | 2.78 | 1.87 | -0.95 | -0.03 |
| Interest Coverage | -36.63 | -36.63 | -43.11 | -89.41 | -42.94 | -7.65 | — | -19.68 | 1.00 | 37.09 | 8.23 |
MYGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Myriad Genetics, Inc.'s current ratio of 2.49x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.01x to 2.49x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.49 | 2.49 | 1.82 | 2.01 | 2.00 | 2.37 | 2.67 | 2.96 | 2.96 | 3.19 | 1.46 |
| Quick Ratio | 2.26 | 2.26 | 1.65 | 1.87 | 1.85 | 2.30 | 2.48 | 2.69 | 2.69 | 2.86 | 1.26 |
| Cash Ratio | 1.12 | 1.12 | 0.62 | 0.90 | 0.84 | 1.66 | 1.03 | 1.16 | 1.16 | 1.77 | 0.69 |
| Asset Turnover | — | 1.17 | 0.82 | 0.66 | 0.57 | 0.52 | 0.39 | 0.41 | 0.54 | 0.66 | 0.63 |
| Inventory Turnover | 8.10 | 8.10 | 9.17 | 10.74 | 10.05 | 12.92 | 6.58 | 5.93 | 6.40 | 5.17 | 4.06 |
| Days Sales Outstanding | — | 51.04 | 52.82 | 55.39 | 54.66 | 48.25 | 58.65 | 79.22 | 59.44 | 48.24 | 52.66 |
MYGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Myriad Genetics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | 0.2% | 4.9% | 1.2% |
| FCF Yield | — | — | — | — | — | 0.0% | — | 6.0% | 3.6% | 4.0% | 5.6% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 2.4% | 0.0% | 1.8% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 2.4% | 0.0% | 1.8% |
| Shares Outstanding | — | $93M | $91M | $83M | $81M | $78M | $75M | $74M | $76M | $72M | $69M |
Peer Comparison
Compare MYGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MYGNYou | $425M | -1.1 | — | — | 69.9% | -8.2% | -68.5% | -8.7% | — |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 VCYT | $4B | 65.4 | 41.4 | 33.8 | 69.6% | 14.3% | 5.3% | 5.6% | 0.4 |
 CDNA | $1B | -65.5 | — | 37.4 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 GH | $17B | -39.7 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 FLGT | $535M | -9.1 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 LH | $21B | 24.5 | 12.6 | 17.5 | 26.8% | 10.9% | 10.5% | 7.8% | 3.3 |
 DGX | $22B | 22.3 | 12.9 | 15.9 | 31.9% | 14.5% | 14.0% | 8.8% | 3.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
MYGN — Frequently Asked Questions
Quick answers to the most common questions about buying MYGN stock.
What is Myriad Genetics, Inc.'s P/E ratio?
Myriad Genetics, Inc.'s current P/E ratio is -1.1x. The historical average is 28.9x.
What is Myriad Genetics, Inc.'s ROE?
Myriad Genetics, Inc.'s return on equity (ROE) is -68.5%. The historical average is -5.3%.
Is MYGN stock overvalued?
Based on historical data, Myriad Genetics, Inc. is trading at a P/E of -1.1x. Compare with industry peers and growth rates for a complete picture.
What are Myriad Genetics, Inc.'s profit margins?
Myriad Genetics, Inc. has 69.9% gross margin and -8.2% operating margin.